Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))

Jordi Bruix; Ann Lii Cheng; Gerold Meinhardt; Keiko Nakajima; Yoriko De Sanctis; Josep Llovet

doi:10.1016/j.jhep.2018.07.015

Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))

Jordi Bruix, Ann Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis, Josep Llovet

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Abstract

It has come to our attention that there are errors in the symbols used in the bottom two rows of Table 2 and the bottom row of Table 3. Please see the corrected Tables below. Please also note that in the online supplementary information there was a similar error in the bottom row of Table S1. An updated online supplementary file is provided with this corrigendum.

Original language	English
Pages (from-to)	990-991
Number of pages	2
Journal	Journal of Hepatology
Volume	69
Issue number	4
DOIs	https://doi.org/10.1016/j.jhep.2018.07.015
State	Published - Oct 2018

Access to Document

10.1016/j.jhep.2018.07.015

Fingerprint

Dive into the research topics of 'Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))'. Together they form a unique fingerprint.

Cite this

Bruix, J., Cheng, A. L., Meinhardt, G., Nakajima, K., De Sanctis, Y., & Llovet, J. (2018). Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026)). Journal of Hepatology, 69(4), 990-991. https://doi.org/10.1016/j.jhep.2018.07.015

@article{76c43f780675403193a55a75a226d649,

title = "Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))",

abstract = "It has come to our attention that there are errors in the symbols used in the bottom two rows of Table 2 and the bottom row of Table 3. Please see the corrected Tables below. Please also note that in the online supplementary information there was a similar error in the bottom row of Table S1. An updated online supplementary file is provided with this corrigendum.",

author = "Jordi Bruix and Cheng, {Ann Lii} and Gerold Meinhardt and Keiko Nakajima and {De Sanctis}, Yoriko and Josep Llovet",

note = "Publisher Copyright: {\textcopyright} 2017 European Association for the Study of the Liver",

year = "2018",

month = oct,

doi = "10.1016/j.jhep.2018.07.015",

language = "English",

volume = "69",

pages = "990--991",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "4",

}

Bruix, J, Cheng, AL, Meinhardt, G, Nakajima, K, De Sanctis, Y & Llovet, J 2018, 'Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))', Journal of Hepatology, vol. 69, no. 4, pp. 990-991. https://doi.org/10.1016/j.jhep.2018.07.015

Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026)). / Bruix, Jordi; Cheng, Ann Lii; Meinhardt, Gerold et al.
In: Journal of Hepatology, Vol. 69, No. 4, 10.2018, p. 990-991.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma

T2 - Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))

AU - Bruix, Jordi

AU - Cheng, Ann Lii

AU - Meinhardt, Gerold

AU - Nakajima, Keiko

AU - De Sanctis, Yoriko

AU - Llovet, Josep

PY - 2018/10

Y1 - 2018/10

N2 - It has come to our attention that there are errors in the symbols used in the bottom two rows of Table 2 and the bottom row of Table 3. Please see the corrected Tables below. Please also note that in the online supplementary information there was a similar error in the bottom row of Table S1. An updated online supplementary file is provided with this corrigendum.

AB - It has come to our attention that there are errors in the symbols used in the bottom two rows of Table 2 and the bottom row of Table 3. Please see the corrected Tables below. Please also note that in the online supplementary information there was a similar error in the bottom row of Table S1. An updated online supplementary file is provided with this corrigendum.

UR - http://www.scopus.com/inward/record.url?scp=85051650852&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2018.07.015

DO - 10.1016/j.jhep.2018.07.015

M3 - Comment/debate

C2 - 30104026

AN - SCOPUS:85051650852

SN - 0168-8278

VL - 69

SP - 990

EP - 991

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 4

ER -

Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026)). Journal of Hepatology. 2018 Oct;69(4):990-991. doi: 10.1016/j.jhep.2018.07.015